Floatz logo

Precemtabart Tocentecan

Metastatic Colorectal Cancer

EMD Serono Research & Development Institute, Inc.antibody_drug_conjugatePhase 3Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

839 Active assets in the Metastatic Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

Precemtabart Tocentecan is also rated in:

neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →